Hikal Ltd.

NSE: HIKAL | BSE: 524735 | ISIN: INE475B01022 |Industry: Pharmaceuticals
|Mid-range Performer

Hikal Ltd.    
28 Oct 2021

Q2FY22 Financial Highlights:

  • Revenue of Rs. 469 crore; YoY growth of 26% 
  • EBITDA of Rs. 91 crore; YoY growth of 30%
  • EBITDA Margin of 19.4%; Expansion of 62 bps
  • PAT of Rs. 44 crores; YoY growth of 63%
Key Highlights:
  • Higher sales of existing products and addition of new products vs Q2 FY21
  • Strong performance in both own products as well as CDMO segment
  • Hikal transformational journey with a global consultant is on track
  • Steady improvement in EBITDA margins continues, aided by improved product mix and higher operating leverage vs Q2 FY21
  • YoY growth of 63% in PAT driven by Product Mix
  • Lowered interest rates 
  • Shutdown of the Mahad facility for 27 days in Q2 FY22 due to heavy rains led to a substantial impact on the revenue & profitability

Commenting on the results, Jai Hiremath, Executive Chairman, Hikal Ltd. said, “Hikal has delivered another quarter of positive performance. From a segmental performance perspective, the Crop Protection business has performed well, registering a positive YoY growth of 105% in Q2 on the back of strong volume growth of our existing products and further scale up of volumes of our new products. We expect this positive momentum to continue in the next few quarters based on a healthy pipeline of products at various stages.

Unusually heavy rainfalls in the Raigad region had a severe impact on our Mahad operations leading to the shutdown of our Mahad facility for several weeks. This led to a loss in sales and profitability for the crop division. Relentless efforts by our teams from all our sites helped in restarting our operations in a staggered manner and we were able to return to normal operations in due course.

Our Pharmaceutical business remained flat due to a slower offtake by customers in this quarter. This was primarily due to several raw material shortages and global logistics issues. We expect raw material challenges to continue in the next few months and are working with both our suppliers and customers to mitigate the price fluctuations.

Our capex plans and our new product launch plans remain intact for both our divisions. We are seeing tailwinds in terms of new opportunities arising from global supply chain disruptions and the China plus one strategy playing out.

Global supply chain challenges coupled with a steep increase in input raw material prices continue to pose a challenge for our industry going forward. We have put in significant efforts over the past few years on developing alternate sourcing partners and backward integration of certain raw materials. While this will help us in the long-term, we do expect certain disruptions in the short term. Over the next several months we expect the situation to normalize.

As part of our efforts to fight the Pandemic, our employees across the company are 100% vaccinated for their first dose and about 75% have been vaccinated for their second dose. We expect to have all our employees fully vaccinated by the year end.

In alignment with our long-term vision and bold aspirations, we have set out on a transformational journey with a Global consultant to create a roadmap across our business verticals. This initiative will drive future growth and profitability, by giving us a new strategic direction and enabling us to chart our progress in a sustainable manner. The journey forward will not just entail accelerating growth in our existing pharma and crop protection businesses but will also see strong growth in our emerging business verticals such as animal health and biocides."

Result PDF

Hikal Ltd. has an average target of 595.00 from 2 brokers.